Serologic Markers: Impact on Early Diagnosis and Disease Stratification in Inflammatory Bowel Disease

References

• . Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53( suppl 5):V1–V16
   Web of Science ®Google Scholar
• . Irvine EJ. Review article: patients' fears and unmet needs in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20( suppl 4):54–59
   PubMed Web of Science ®Google Scholar
• . Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther. 2002;16(9):1603–1609
   PubMed Web of Science ®Google Scholar
• . Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis. 2008;14(4):554–565
   PubMed Web of Science ®Google Scholar
• . Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(3):272–286
   PubMed Web of Science ®Google Scholar
• . Marrero F, Qadeer MA, Lashner BA. Severe complications of inflammatory bowel disease. Med Clin North Am. 2008;92(3):671–686, ix
   PubMed Web of Science ®Google Scholar
• . Lichtenstein GR, Hanauer SB, Sandborn WJ, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104(2):465–483
   PubMed Web of Science ®Google Scholar
• . Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology. 2004;126(6):1550–1560
   PubMed Web of Science ®Google Scholar
• . Cosnes J, Cattan S, Blain A,. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8(4):244–250
   PubMed Web of Science ®Google Scholar
• . Rubin G, De WN, Meineche-Schmidt V, Seifert B, Hall N, Hungin P. The diagnosis of IBS in primary care: consensus development using nominal group technique. Fam Pract. 2006;23(6):687–692
   PubMed Web of Science ®Google Scholar
• . Jess T, Loftus EV Jr, Velayos FS,. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology. 2006;130(4):1039–1046
   PubMed Web of Science ®Google Scholar
• . Dhillon SL, Loftus EV, Tremaine WJ. The natural history of surgery for Crohn's disease in a population-based cohort from Olmsted County, Minnesota [abstract 825]. Am J Gastroenterol. 2005;100( suppl):S305
   Web of Science ®Google Scholar
• . Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99(7):1371–1385
   PubMed Web of Science ®Google Scholar
• . Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641–1657
   PubMed Web of Science ®Google Scholar
• . Odze R. Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol. 2003;16(4):347–358
   PubMed Web of Science ®Google Scholar
• . Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126(6):1518–1532
   PubMed Web of Science ®Google Scholar
• . Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–431
   PubMed Web of Science ®Google Scholar
• . The Voices of Crohn's. 2008. http://www.voicesofcrohns.com/voicesofcrohns/pages/voices/key_findings.jsp. Accessed December 1, 2008
   Google Scholar
• . Burgmann T, Clara I, Graff L,. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis—how much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006;4(5):614–620
   PubMed Web of Science ®Google Scholar
• . Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88(11):995–1000
   PubMed Web of Science ®Google Scholar
• . Sainsbury A, Heatley RV. Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;21(5):499–508
   PubMed Web of Science ®Google Scholar
• . Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology. 1988;95(6):1523–1527
   PubMed Web of Science ®Google Scholar
• . Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol. 2007;23(4):365–369
   PubMed Web of Science ®Google Scholar
• . Young Y, Abreu MT. Advances in the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep. 2006;8(6):470–477
   PubMedGoogle Scholar
• . Hugot JP, Chamaillard M, Zouali H,. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599–603
   PubMed Web of Science ®Google Scholar
• . Reese GE, Constantinides VA, Simillis C,. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101(10):2410–2422
   PubMed Web of Science ®Google Scholar
• . Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M. IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007;13(12):1561–1566
   PubMed Web of Science ®Google Scholar
• . Targan SR, Landers CJ, Yang H,. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128(7):2020–2028
   PubMed Web of Science ®Google Scholar
• . Brandwein SL, McCabe RP, Cong Y,. Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J Immunol. 1997;159(1):44–52
   PubMed Web of Science ®Google Scholar
• . Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52(2):171–181
   PubMed Web of Science ®Google Scholar
• . Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133(5):1670–1689
   PubMed Web of Science ®Google Scholar
• . Mow WS, Vasiliauskas EA, Lin YC,. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126(2):414–424
   PubMed Web of Science ®Google Scholar
• . Dubinsky MC, Lin YC, Dutridge D,; Western Regional Pediatric IBD Research Alliance. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101(2):360–367
   PubMed Web of Science ®Google Scholar
• . Dubinsky MC, Kugathasan S, Mei L,. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6(10):1105–1111
   PubMed Web of Science ®Google Scholar
• . Eliakim R, Suissa A, Yassin K, Katz D, Fischer D. Wireless capsule video endoscopy compared to barium follow-through and computerised tomography in patients with suspected Crohn's disease—final report. Dig Liver Dis. 2004;36(8):519–522
   PubMedGoogle Scholar
• . Joossens S, Reinisch W, Vermeire S,. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122(5):1242–1247
   PubMed Web of Science ®Google Scholar
• . Geboes K, Colombel JF, Greenstein A,. Indeterminate colitis: a review of the concept—what's in a name? Inflamm Bowel Dis. 2008;14(6):850–857
   PubMed Web of Science ®Google Scholar
• . Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4819–4831
   PubMed Web of Science ®Google Scholar
• . Yantiss RK, Odze RD. Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology. 2006;48(2):116–132
   PubMed Web of Science ®Google Scholar
• . Martland GT, Shepherd NA. Indeterminate colitis: definition, diagnosis, implications and a plea for nosological sanity. Histopathology. 2007;50(1):83–96
   PubMed Web of Science ®Google Scholar
• . Rogers BH, Clark LM, Kirsner JB. The epidemiologic and demographic characteristics of inflammatory bowel disease: an analysis of a computerized file of 1400 patients. J Chronic Dis. 1971;24(12):743–773
   PubMedGoogle Scholar
• . Kent TH, Ammon RK, DenBesten L. Differentiation of ulcerative colitis and regional enteritis of colon. Arch Pathol. 1970;89(1):20–29
   PubMedGoogle Scholar
• . Tremaine WJ. Review article: Indeterminate colitis—definition, diagnosis and management. Aliment Pharmacol Ther. 2007;25(1):13–17
   PubMed Web of Science ®Google Scholar
• . Carvalho RS, Abadom V, Dilworth HP, Thompson R, Oliva-Hemker M, Cuffari C. Indeterminate colitis: a significant subgroup of pediatric IBD. Inflamm Bowel Dis. 2006;12(4):258–262
   PubMed Web of Science ®Google Scholar
• . Israeli E, Grotto I, Gilburd B,. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54(9):1232–1236
   PubMed Web of Science ®Google Scholar
• . Markowitz J, Kugathasan S, Dubinsky M,. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis. 2009;15(5):714–719
   PubMed Web of Science ®Google Scholar
• . Landers CJ, Cohavy O, Misra R,. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;123(3):689–699
   PubMed Web of Science ®Google Scholar
• . Mundwiler ML, Mei L, Landers CJ, Reveille JD, Targan S, Weisman MH. Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study. Arthritis Res Ther. 2009;11(6):R177
   Web of Science ®Google Scholar
• . Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96(3):730–734
   PubMed Web of Science ®Google Scholar
• . Terjung B, Worman HJ. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001;15(4):629–642
   PubMed Web of Science ®Google Scholar
• . Terjung B, Bogsch F, Klein R,. Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis. Eur J Med Res. 2004;9(9):439–448
   PubMed Web of Science ®Google Scholar
• . Sostegni R, Daperno M, Ercole E,. Detection of anti-Saccharomyces cerevisiae antibodies in Crohn's disease: is it a reliable diagnostic and prognostic marker? Dig Liver Dis. 2001;33(9):755–761
   PubMedGoogle Scholar
• . Ferrante M, Henckaerts L, Joossens M,. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56(10):1394–1403
   PubMed Web of Science ®Google Scholar
• . Fleshner PR, Vasiliauskas EA, Kam LY,. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut. 2001;49(5):671–677
   PubMed Web of Science ®Google Scholar
• . Dotan I, Fishman S, Dgani Y,. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006;131(2):366–378
   PubMed Web of Science ®Google Scholar
• . Vasiliauskas EA, Plevy SE, Landers CJ,. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996;110(6):1810–1819
   PubMed Web of Science ®Google Scholar
• . Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47(4):487–496
   PubMed Web of Science ®Google Scholar
• . Fleshner P, Ippoliti A, Dubinsky M,. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6(5):561–568
   PubMed Web of Science ®Google Scholar
• . Papp M, Altorjay I, Dotan N,. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103(3):665–681
   PubMed Web of Science ®Google Scholar
• . Desir B, Amre DK, Lu SE,. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol. 2004;2(2):139–146
   PubMed Web of Science ®Google Scholar
• . Feagan BG, Panaccione R, Sandborn WJ,. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008;135(5):1493–1499
   PubMed Web of Science ®Google Scholar
• . Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128(4):862–869
   PubMed Web of Science ®Google Scholar
• . Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Li J. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Abstract 985. Presented at: American Gastroenterological Association Institute and Digestive Disease Week Annual Meeting; 2007
   Google Scholar
• . Sandborn WJ, Colombel JF, Panes J, Scholmerich J, McConnell J, Schreiber S. Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset Crohn's disease: data from PRECiSE 2 [abstract 1109]. Am J Gastroenterol. 2006;101:S454–S455
   Web of Science ®Google Scholar
• . Sandborn WJ, Rutgeerts P, Reinisch W,. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine in patients with crohn's disease naive to immunomodulators and biologic therapy. Late-breaking abstract 29. Presented at: 73rd Annual Scientific Meeting and Postgraduate Course of the American College of Gastroenterology, Kissimmee, FL; October 3–8, 2008, Kissimmee, FL
   Google Scholar
• . D'Haens G, Baert F, Van Assche G,. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371(9613):660–667
   PubMed Web of Science ®Google Scholar
• . Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis. 2009;15(10):1570–1582
   PubMed Web of Science ®Google Scholar
• . Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. 2008;14(43):6641–6647
   PubMed Web of Science ®Google Scholar